Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about REPL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Vusolimogene Oderparepvec | Advanced Melanoma | Phase 3 · NCT06264180 | Recruiting |
| Single-agent chemotherapy | Advanced Melanoma | Phase 3 · NCT06264180 | Recruiting |
| Sturlimogene Erparepvec | Metastatic Uveal Melanoma | Phase 2/3 · NCT06581406 | Recruiting |
| Oncolytic Herpes Simplex Virus-1 Expressing… | Refractory Metastatic Colorectal Cancer | Phase 2 · NCT05733611 | Terminated |
Also used in these trials (approved or third-party drugs, not REPL's own candidates): Ipilimumab, Nivolumab, Relatlimab, Pembrolizumab, Atezolizumab, Pegfilgrastim, Filgrastim, Durvalumab, Cemiplimab, Bevacizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
REPL holds $307.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $61.7M/quarter from operations, an estimated runway of 15 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when REPL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 11,075,336 | 11.68% | 2026-08-09 |
| Blackrock Inc. | Institution (13F) | 8,799,007 | 9.28% | 2026-09-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 7,356,916 | 7.76% | 2026-03-31 |
| Montanova Capital, LLC | Institution (13G, 5%+) | 6,609,000 | 6.97% | 2026-07-30 |
| Boxer Capital Management, LLC | Institution (13F) | 4,278,159 | 4.51% | 2026-09-30 |
| Suvretta Capital Management, LLC | Institution (13G, 5%+) | 4,221,836 | 4.45% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 4,174,260 | 4.40% | 2026-09-30 |
| Marshall Wace LLP | Institution (13F) | 3,815,373 | 4.02% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 3,395,553 | 3.58% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 3,322,524 | 3.50% | 2026-09-30 |
| AQR Capital Management, LLC | Institution (13F) | 2,308,478 | 2.44% | 2026-09-30 |
| Philip Astley-Sparke Director · +75,000 options |
Insider | 1,362,414 | 1.44% | 2026-08-20 |
Share count 94,800,404 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-09 filed 2026-11-10 |
SLATTERY JOSEPH P |
Sale (S) | 5,200 | $21.80 | 1,467 |
| 2026-11-02 filed 2026-11-03 |
Dhingra Kapil |
Option exercise (M) | 43,169 | $1.75 | 43,169 |
| 2026-11-02 filed 2026-11-03 |
Dhingra Kapil |
Sale (S) | 21,500 | $19.00 | 21,669 |
| 2026-11-02 filed 2026-11-03 |
Dhingra Kapil |
Option exercise (M) | 43,169 | – | – |
| 2026-08-20 filed 2026-08-24 |
Astley-Sparke Philip |
Gift (G) | 50,000 | – | 1,362,414 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-04-10 | vusolimogene oderparepvec | BLA | -28.2% | -19.5% | -62.9% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REPL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →